Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Travere Therapeutics to post earnings of ($0.05) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Travere Therapeutics Trading Down 0.3%

NASDAQ:TVTX opened at $30.22 on Thursday. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The firm has a market capitalization of $2.70 billion, a P/E ratio of -28.51, a PEG ratio of 0.83 and a beta of 0.83. The company’s 50-day simple moving average is $33.50 and its 200 day simple moving average is $28.28. Travere Therapeutics has a one year low of $12.91 and a one year high of $42.13.

Insider Buying and Selling

In other Travere Therapeutics news, CEO Eric M. Dube sold 100,087 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $32.28, for a total transaction of $3,230,808.36. Following the sale, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at $13,973,560.08. The trade was a 18.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jula Inrig sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $42.00, for a total value of $630,000.00. Following the completion of the sale, the insider directly owned 88,787 shares of the company’s stock, valued at $3,729,054. The trade was a 14.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 331,925 shares of company stock valued at $11,318,755 in the last quarter. 4.19% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth about $33,000. State of Wyoming bought a new stake in Travere Therapeutics in the fourth quarter worth about $37,000. Headlands Technologies LLC purchased a new position in shares of Travere Therapeutics during the second quarter valued at approximately $73,000. Empowered Funds LLC bought a new position in shares of Travere Therapeutics during the fourth quarter valued at approximately $115,000. Finally, Parallel Advisors LLC grew its stake in shares of Travere Therapeutics by 384.0% during the fourth quarter. Parallel Advisors LLC now owns 3,785 shares of the company’s stock valued at $145,000 after buying an additional 3,003 shares during the last quarter.

Analysts Set New Price Targets

TVTX has been the topic of a number of recent research reports. Zacks Research cut Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a report on Friday, November 28th. Piper Sandler boosted their price objective on shares of Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Guggenheim reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Finally, TD Cowen restated a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.